Form 8-K ALNYLAM PHARMACEUTICALS, For: Aug 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Alnylam Pharmaceuticals (ALNY) PT Raised to $300 at RBC Capital
August 2, 2024 6:21 AM EDTRBC Capital analyst Luca Issi raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $300.00 (from $265.00) while maintaining a Outperform rating.
The analyst comments "Strong beat and raise with $410m product revenue ahead of consensus ($367m) and guide raised 11% at the... More
